Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target With Disease Severity and Mortality In Systemic Sclerosis
Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target With Disease Severity and Mortality In Systemic Sclerosis
Chemomab 報告了新的同行評審出版物，強化了其 CCL24 靶點與系統性硬化症疾病嚴重程度和死亡率的臨床關係
Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), Showing that It is Associated with Disease Severity Across the Fibrotic and Vascular Manifestations of SSc
對 200 多名現實世界患者群體的縱向研究進一步證實 CCL24 是系統性硬化 (ssC) 的新靶標，表明它與 ssC 的纖維化和血管表現形式中的疾病嚴重程度有關
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。